Efikasnost i djelotvornost vakcina protiv COVID-19 širom svijeta: mini-pregled i meta-analiza.
Annals of clinical microbiology and antimicrobials
Sažetak istraživanja
Ciljevi Ova meta-analiza procijenila je djelotvornost i djelotvornost nekoliko vakcina protiv COVID-19, uključujući AstraZeneca, Pfizer, Moderna, Bharat i Johnson & Johnson, kako bi se bolje procijenila njihova imunogenost, prednosti ili nuspojave.
Metode Uključene su studije koje izvještavaju o djelotvornosti i djelotvornosti vakcina protiv COVID-19 od novembra 2020. do aprila 2022. Izračunata je objedinjena efektivnost/efikasnost sa intervalom pouzdanosti od 95% (95% CI) sa Metaprop redosledom.
Rezultati su prikazani na šumskim parcelama. Urađene su i unapred definisane analize podgrupa i analize osetljivosti.
Rezultati U ovu metaanalizu uključeno je ukupno dvadeset članaka. Nakon prve doze vakcine, ukupna efikasnost svih vakcina protiv COVID-19 u našoj studiji bila je 71% (95% CI 0,65, 0,78). Ukupna efikasnost vakcina nakon druge doze bila je 91% (95% CI 0,88, 0,94)). Ukupna efikasnost vakcina nakon prve i druge doze bila je 81% (95% CI 0,70, 0,91) i 71% (95% CI 0,62, 0,79), respektivno. Efikasnost vakcine Moderna nakon prve i druge doze bila je najveća među ostalim ispitivanim vakcinama ((74% (95% CI, 0,65, 0,83) i 93% (95% CI, 0,89, 0,97), respektivno). Najveća ukupna efikasnost prve doze ispitivanih vakcina (varijanta Gamma,%759%) 0,73, 0,75)), a najveća efikasnost nakon druge doze uočena je u odnosu na Beta varijantu (96% (95% CI, 0,96, 0,96) Efikasnost za AstraZeneca i Pfizer vakcine nakon prve doze bila je 78% (95% CI, 0,49% CI, 0,49%). 0,77, 0,92), Efikasnost druge doze za AstraZeneca, Pfizer i Bharat bila je 67% (95% CI, 0,54, 0,80), 93% (95% CI, 0,85, 1,00) i 71% (95,6% CI, respektivno). Efikasnost prve i druge doze vakcinacije protiv Alfa varijante bila je 84% (95% CI, 0,84, 0,84) i 77% (95% CI, 0,57, 0,97), respektivno, što je najveća među ostalim varijantama. Općenito, primjena druge doze je proizvela pouzdaniji odgovor i veću djelotvornost od pojedinačne doze.
Prikaži originalni naslov i sažetak na engleskom
The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis.
Objectives This meta-analysis evaluated the Efficacy and Effectiveness of several COVID-19 vaccines, including AstraZeneca, Pfizer, Moderna, Bharat, and Johnson & Johnson, to better estimate their immunogenicity, benefits, or side effects.
Methods Studies reporting the Efficacy and Effectiveness of COVID-19 vaccines from November 2020 to April 2022 were included. The pooled Effectiveness/Efficacy with a 95% confidence interval (95% CI) with Metaprop order was calculated. The results were presented in forest plots. Predefined subgroup analyses and sensitivity analyses were also performed.
Results A total of twenty articles were included in this meta-analysis. After the first dose of the vaccine, the total effectiveness of all COVID-19 vaccines in our study was 71% (95% CI 0.65, 0.78). The total effectiveness of vaccines after the second dose was 91% (95% CI 0.88, 0.94)). The total efficacy of vaccines after the first and second doses was 81% (95% CI 0.70, 0.91) and 71% (95% CI 0.62, 0.79), respectively. The effectiveness of the Moderna vaccine after the first and second dose was the highest among other studied vaccines ((74% (95% CI, 0.65, 0.83) and 93% (95% CI, 0.89, 0.97), respectively). The highest first dose overall effectiveness of the studied vaccines was against the Gamma variant (74% (95% CI, 0.73, 0.75)), and the highest effectiveness after the second dose was observed against the Beta variant (96% (95% CI, 0.96, 0.96)). The Efficacy for AstraZeneca and Pfizer vaccines after the first dose was 78% (95% CI, 0.62, 0.95) and 84% (95% CI, 0.77, 0.92), respectively. The second dose Efficacy for AstraZeneca, Pfizer, and Bharat was 67% (95% CI, 0.54, 0.80), 93% (95% CI, 0.85, 1.00), and 71% (95% CI, 0.61, 0.82), respectively. The overall efficacy of first and second dose vaccination against the Alfa variant was 84% (95% CI, 0.84, 0.84) and 77% (95% CI, 0.57, 0.97), respectively, the highest among other variants.
Conclusion mRNA-based vaccines against COVID-19 showed the highest total efficacy and effectiveness than other vaccines. In general, administering the second dose produced a more reliable response and higher effectiveness than a single dose.
Izvorni podaci
- DOI
- 10.1186/s12941-023-00594-y
- PMID
- 37208749
- PMCID
- PMC10198032
- Provjereno
- 2026-07-26
Naslov i sažetak prevedeni su automatski i prijevod može sadržavati netačnosti ili neprecizne stručne izraze. Za sve detalje, citiranje i medicinsko tumačenje pregledajte originalnu englesku verziju članka. Ne donosite zdravstvene odluke samo na osnovu ovog prijevoda.
Pregledaj originalni članak na engleskom